Karyopharm Therapeutics Inc - Pris och diagram FX Empire

Stocks in Play – Bioinvent rasar efter kapitalanskaffning

by Vandana Singh 1 min Karyopharm shares tank after FDA insiders slam their case on the efficacy of a cancer drug with “significant toxicity”. John Carroll. Editor & Founder. Karyopharm's Next Event. Q1 2021 Karyopharm Therapeutics Inc Earnings Release May 03, 2021 3 months ago. Karyopharm Therapeutics Posts Q4 Loss Per Share $0.59. Feb 9, 2021 is giving Karyopharm Therapeutics Inc (KPTI) an Analyst Rating Rank of 69, meaning KPTI is ranked higher by analysts than 69% of stocks.

Karyopharm stock

The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KPTI will outperform the market and that investors should add to their positions of Karyopharm Therapeutics. View the latest ratings for KPTI. Karyopharm Therapeut is trading at 10.55 as of the 7th of April 2021. This is a 0.76 percent increase since the beginning of the trading day. The stock's open price was 10.47. Get the latest Karyopharm Therapeut detailed stock quotes, stock trade data, stock price info, and performance analysis, including Karyopharm investment advice, charts, stats and more.

$ONCO - Търсене в Twitter

2021-04-16 · KPTI | Complete Karyopharm Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. 9 Wall Street analysts have issued twelve-month target prices for Karyopharm Therapeutics' stock.

Kpti

Historical Stock Prices are provided for informational purposes only and are not intended for trading purposes. Karyopharm Therapeutics Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. 2020-04-27 · Karyopharm Therapeutics currently has a Zacks Rank of #1 (Strong Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market 2021-04-11 · Currently, the analyst consensus on Karyopharm Therapeutics is a Strong Buy with an average price target of $30.40, representing a 201.9% upside. In a report issued on March 30, H.C. Wainwright also maintained a Buy rating on the stock with a $49.00 price target.

This suggests a possible upside of 210.6% from the stock's current price. Karyopharm Stock Is Trading Higher After China's NMPA Signs Off Early-Stage ATG-019 Study In Cancer Settings. The National Medical Products Administration (NMPA) has approved Antengene Corporation Karyopharm Stock Is Trading Higher After China's NMPA Signs Off Early-Stage ATG-019 Study In Cancer Settings The National Medical Products Administration (NMPA) has approved Antengene Corporation Limited's Investigational New Drug Application for a Phase 1 trial of ATG-019 in China. 2021-04-22 · Karyopharm Therapeutics NASDAQ Updated Apr 22, 2021 11:56 PM. KPTI 9.62 0.03 (0.31%). Post-Market 0.04 (0.42%) Karyopharm Therapeutics (KPTI) stock price prediction is 12.398137 USD. The Karyopharm Therapeutics stock forecast is 12.398137 USD for 2022 April 22, Friday; and 18.667 USD for 2026 April 22, Wednesday with technical analysis.
Anabola steroider män

Low volume, high quality. Tweets are not recommendations to buy or sell any security.

Marketplace Bio. Follow. Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer.
Är parkering tillåten efter gångfartsområde

arv syskon hus
musikskolan huddinge
valja skola stockholm
positiva ledaregenskaper
modified endowment contract

Search Results köp Vigora i sverige - Todays BIG Stock

Benzinga-5.76%. Apr-01-21 08:00AM : Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire.

Försäkringskassan handläggningstid sjukpenning
vår årstid engelska

Search Results köp Vigora i sverige - Todays BIG Stock

9 Wall Street analysts have issued twelve-month target prices for Karyopharm Therapeutics' stock. Their forecasts range from $22.00 to $41.00. On average, they expect Karyopharm Therapeutics' stock price to reach $29.88 in the next twelve months. This suggests a possible upside of 210.6% from the stock's current price.